By Khushi Malhotra and Dharamraj Dhutia MUMBAI, Sept 29 (Reuters) - India's Sun Pharmaceutical Industries is planning to ...
Lerodalcibep licensing deal, growth in the US portfolio and tariff relief offer triggers, while the proposed Organon ...
In den Vereinigten Staaten ist das Präparat als Lerochol durch die FDA zugelassen; diese Marke und der entsprechende Markt ...
LIB Therapeutics Inc. und Sun Pharmaceutical Industries Limited haben eine exklusive Lizenzvereinbarung bekannt gegeben, die ...
Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715; together with its subsidiaries and/or associated companies, "Sun Pharma") and LIB Therapeutics ...
India’s largest drugmaker by market capitalisation plans to raise around Rs 10,000 crore through domestic bonds to partly ...
Sun Pharma will be responsible for pursuing regulatory approvals in licensed territories where approval has not yet been obtained. The excluded China territory comprises mainland China, Hong Kong, ...
LIB Therapeutics and Sun Pharma announce manufacturing agreement for Lerodalcibep, a PCSK9 Inhibitor
Lerodalcibep is approved in the EU under the brand name Lyrokaul for the treatment of adult patients with ...
16d
"sun-pharma"
Sun Pharma will acquire US-based Organon & Co in an all-cash deal valued at USD 11.75 billion. The acquisition will strengthen its global presence, expand women’s health portfolio, and position the ...
Mumbai-based Sun Pharmaceutical Industries and US-based LIB Therapeutics Inc. have announced an exclusive licensing agreement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results